documented as adverse event (AE) in 17.9% (22 episodes) and 7.5% (13 episodes), respectively (P = 0.025). Severe episodes were reported in 3.9% of IS and 1.7% of vildagliptin patients. 10.4% of IS and 2.6% of vildagliptin patients reported severe episodes and/or unscheduled medical visits due to hypoglycemia (P = 0.029). Glycemic control remained stable in both cohorts. Compliance with fasting was high, as well as adherence to drug with C5 missed-dose for 15.4% of IS and 8.5% of vildagliptin patients. Conclusion: Although the overall frequency of malaise suggestive of hypoglycemia was high, which would be expected with prolonged fasting in a well-controlled T2DM population during hot summer days, the incidence of more severe and better-documented episodes (AE, severe event, event leading to unscheduled medical visit) were much lower, with consistently less events with vildagliptin therapy.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease with a worldwide prevalence that is rapidly increasing. In 2012, more than 371 million people were estimated to have T2DM [1] . As a result of urbanization and socioeconomic developments, the prevalence of diabetes has been rising by 10% annually in countries with large Muslim populations [2] .
Almost a quarter (*1.6 billion) of the world's population follows Islam [3, 4] . Although a majority of them are spread across the Middle East, North Africa, and parts of Asia, there are about 4 million Muslims in France [5] .
Ramadan is the ninth month of the Islamic lunar calendar, when healthy Muslims are obliged to abstain from food and drinks from sunrise to sunset [6] . Although the Koran [7] and several guidelines [4, 8, 9] exempt the sick from fasting, over 50 million Muslims with diabetes fast during the holy month of Ramadan each year worldwide [3, 10] . Epidemiologic data from the first large retrospective study (EPIdemiology of DIAbetes and Ramadan [EPIDIAR]) conducted in 13 Islamic countries reported that a vast majority of patients with T2DM (79%) fasted for at least 15 days during Ramadan [11] . The dates of observance of Ramadan differ each year and the period of fasting also varies by geographical location and season, lasting up to 18 h or more during the summer months in the northern latitudes [4] . A majority of Muslim patients with diabetes are ardent about their Ramadan fasting, despite the potential complications of fasting, which may include hyperglycemia, hypoglycemia, and increased risk of dehydration and thrombosis [10, 12] .
Prolonged fasting in the absence of adequate insulin may lead to excessive glycogen breakdown and increased gluconeogenesis, eventually leading to hyperglycemia [4, 10] . On the other hand, the risk of hypoglycemia is an important factor to be considered when choosing an antidiabetic agent [10] . This is of particular concern in the coming decade, as
Ramadan will fall during the summer months, increasing the number of fasting hours and eventually raising the risk of negative effects in patients with diabetes who wish to fast.
Hypoglycemia is one of the main health risks during this fasting period [12] . In the EPIDIAR study, there was a 7.5-fold increase in risk of severe hypoglycemia leading to hospitalization during the month of Ramadan as compared with other months (from 0.4 to 3 events/100 patients/month) in patients with T2DM [11] .
The various recommendations for patients with diabetes who wish to fast include pre-Ramadan assessments, Ramadan-focused structured education, and regular blood glucose monitoring [4, 8, 9, 12, 13] .
Sulphonylureas (SUs) and glinides are still widely used as oral antidiabetic agents during Ramadan because of their well-established clinical profiles and low cost [14, 15] , but they are associated with an increased risk of hypoglycemia, and their use should be individualized with caution [4] . Highly variable rates of hypoglycemia have been reported in published studies with SUs and glinides [16] , ranging from 3% in the GLImepiride in RAmadan (GLIRA) study [17] and about 40% in the Vildagliptin Experience Compared To gliclazide Observed during Ramadan (VECTOR) study [18] . A recent fivecountry, observational study that included approximately 1,400 patients treated with SUs during Ramadan reported that the overall incidence of symptomatic hypoglycemic events was approximately 20% and the overall incidence of severe hypoglycemic events was 6.7%, with differences noted across countries and SUs (glipizide 28%, glibenclamide 26%, glimepiride 17%, and gliclazide 14%) [19] .
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been shown to be effective and well tolerated with a low incidence of hypoglycemia in clinical trials up to 2 years across disease stages [20] , including in higherrisk populations with more severe consequences of hypoglycemia, such as in elderly patients aged C75 years [21] , patients with renal impairment [22] , and insulin-treated patients [23] . The risk of severe hypoglycemia has been shown to be significantly reduced with vildagliptin versus SUs [24, 25] . who were either pregnant or breast-feeding were excluded from the study.
MATERIALS AND METHODS

Study Design
Study Assessments
The primary assessment was to evaluate the incidence of all hypoglycemic episodes during Ramadan in each of the 2 treatment cohorts. Hypoglycemic episodes were categorized as symptomatic; confirmed by self-monitoring using a glucometer (defined as B70 mg/dL);
severe (defined by the need of a third party);
reported as an adverse events (AE); and requiring an unscheduled medical visit. 
Statistical Analysis
Quantitative or continuous variables were described by mean and standard deviation (SD) and in some cases by median and range.
Qualitative variables were described by absolute frequency and percentage per modality. 
RESULTS
Patient Disposition and Baseline Characteristics
A total of 218 patients (n = 115 for vildagliptin and n = 83 for IS) were included in the study. 
DISCUSSION
Despite the Islamic rule of exemption, many Muslim patients with diabetes choose to fast during Ramadan [11] . Additionally, fasting has been associated with a feeling of improvement in overall well-being, having a positive impact on social, cultural, and religious domains [28] . Health care professionals are seldom included in the spiritual decision as to whether or not a patient chooses to fast during Ramadan [27, 28] .
The recent study by Gaborit and colleagues in France showed that many GPs had limited medical knowledge of Ramadan fasting in patients with diabetes, leading to over half of them proscribing fasting, even when it was not medically justified. On the other hand, 53% of patients fasted against medical advice. This wide gap between GPs' and patients' attitudes highlights the lack of training and subsequent difficulties in such cross-cultural patientphysician relationships [27] . However, structured educational programs, such as the Ramadan Education and Awareness in Diabetes (READ) program, have clearly shown positive effects [28] , in particular in minimizing the risk of hypoglycemia [29, 30] . This Ramadanfocused diabetes education needs to involve not just the health care team but also the patients' families, friends, community, and Diabetes Ther (2013) 4:385-398 393 religious authorities. It empowers patients to adapt their lifestyle and also helps them take responsibility for their care beyond the Ramadan fast [29, 31, 32] . In addition to these educational programs, newer pharmacologic agents with a reduced risk of hypoglycemia, such as DDP-4 inhibitors, may be a safer option for patients with diabetes during fasting [4, 11] . In view of that consideration, the current prospective, real-life study primarily aimed to compare the incidences of hypoglycemia during (61.5%) patients receiving gliclazide [25] . Similarly, in a UK observational study of South Asian patients, VECTOR, none of the 23 patients treated with vildagliptin as add-on to metformin reported hypoglycemia during Ramadan, in contrast to the 15 (41.7%) patients receiving SU therapy [17] been shown to be better than that reported with SU in the VECTOR study [34] . Treatment adherence was also high overall in the VIRTUE study, but with a similar number of missed doses between cohorts [33] . Besides, compliance to fasting was important in the present study, with patients fasting on average for 29.8 days.
Only about one-fourth of patients (21.7% on vildagliptin and 25.6% on IS) reported a temporary diabetes-related interruption of fasting for C1 day. Conversely, daily consumption of sweets is often increased during Ramadan with iftar, the main meal breaking the fast, being a festive time, but information on total daily food/sugar intake was not collected in the study.
Finally, in the VERDI study, GPs seemed to plan less therapeutic adjustments and treatment modifications for vildagliptintreated patients during Ramadan, which suggests that physicians are more at ease when prescribing DPP-4 inhibitors in this context of fasting. This is not surprising, in view of the low propensity of DPP-4 inhibitors to cause hypoglycemia. DPP-4 inhibitors can be considered as an alternative to SUs for vulnerable patients at high risk for hypoglycemia [3, 20] . For instance, the use of DPP-4 inhibitors in the elderly in reallife practice was associated with a lower incidence of hypoglycemic events (6.4%) versus SU or glinides (26%) over 6 months despite a similar improvement in glucose control [35] . Convincing data have started to accumulate for the use of DPP-4 inhibitors in other situations that increase the risk of hypoglycemia such as prolonged fasting during Ramadan [18, 26, 36, 37] . In addition to the data already described with vildagliptin, studies with sitagliptin have been published. In a large, open-label trial in T2DM patients from India and Malaysia, patients were randomized to either remain on their pre-study SU regimen or to switch to sitagliptin 100 mg. Of a total 848 patients, 3.8% of sitagliptin-treated patients (n = 421) and 7.3% of the SU-treated patients (n = 427) recorded C1 hypoglycemic events during Ramadan [37] . Similarly, in another open-label, randomized study, 1,021 patients from the Middle East were either switched to sitagliptin or remained on their pre-study SU regimen, and 6.7% of the patients in the sitagliptin group compared with 13.2% in the SU group recorded C1 event of symptomatic hypoglycemia [36] .
The current study has several limitations. 
